Choosing a blood thinner based on your genes after complex heart treatment
Part of Heart & circulation clinical trials.
This trial tests whether choosing a blood thinner based on your DNA can prevent more heart problems. If you've had a complex heart procedure, you may be able to get a medication that works best for your body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have had an acute coronary syndrome (like a heart attack or unstable angina) and a complex heart procedure (stenting).
- You are willing to take two blood thinners (one is aspirin) for at least 3 months after the procedure.
- You are willing to give a blood sample for genetic testing.
- Your heart procedure had at least one complex feature (like multiple stents, a blocked artery, or a very calcified lesion).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether using a genetic test to choose your blood thinner (clopidogrel or ticagrelor) can improve how well the medication works. You may qualify if you have stable heart disease or a recent heart attack and are scheduled for a stent procedure.
This trial looks at whether using clopidogrel by itself (without aspirin) works for people after a new drug-eluting stent, based on a blood test of how your body processes the drug. It may help reduce “extra blood-thinning” if you have a certain genetic type that responds well to clopidogrel.
This trial tests whether using a rapid genetic test to choose antiplatelet medication can improve outcomes for people who have had a stroke or mini-stroke. The test checks a gene that affects how your body processes a common antiplatelet drug, so your doctors can pick the safest and most effective medicine for you.
This trial compares two ways to choose blood thinners after a heart attack in people at high risk for bleeding. One way uses a genetic test to guide the choice, while the other uses a different approach.
This trial tests whether a quick genetic test can help choose the right antiplatelet medicine for people who have had a mild stroke or a high-risk mini-stroke (TIA). The goal is to see if this personalized approach is possible in a hospital setting.
This trial compares using a genetic test to choose between two anti-clot medications (clopidogrel and ticagrelor) versus the usual approach of giving clopidogrel alone. It aims to see if personalized treatment can better prevent strokes in people with narrowed brain arteries.
Hear when a new CYP2C19 Polymorphism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.